Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Capital Expenditures: 2014-2024

Historic Capital Expenditures for Aclaris Therapeutics (ACRS) over the last 11 years, with Dec 2024 value amounting to $121,000.

  • Aclaris Therapeutics' Capital Expenditures was N/A to $23,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $73,000, marking a year-over-year change of. This contributed to the annual value of $121,000 for FY2024, which is 90.76% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Capital Expenditures of $121,000 as of FY2024, which was down 90.76% from $1.3 million recorded in FY2023.
  • In the past 5 years, Aclaris Therapeutics' Capital Expenditures ranged from a high of $1.3 million in FY2023 and a low of $121,000 during FY2024.
  • Its 3-year average for Capital Expenditures is $678,333, with a median of $605,000 in 2022.
  • As far as peak fluctuations go, Aclaris Therapeutics' Capital Expenditures soared by 116.36% in 2023, and later tumbled by 90.76% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Capital Expenditures (Yearly) stood at $453,000 in 2020, then plummeted by 32.01% to $308,000 in 2021, then spiked by 96.43% to $605,000 in 2022, then soared by 116.36% to $1.3 million in 2023, then tumbled by 90.76% to $121,000 in 2024.